Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Cigarette smoking still more rampant than vaping among IBD patients

Tristan Manalac
21 Feb 2020
Fan worries smokers might switch to e-cigarettes as an alternative.

E-cigarette use remains low among adult patients with inflammatory bowel disease (IBD), and among these users, conventional cigarette smoking still remains prevalent, according to a recent study presented at the Crohn’s and Colitis Congress (CCC) 2020.

“Cigarette smoking can negatively affect treatment response in IBD patients, especially among those with Crohn’s disease (CD),” said researchers, noting that while it is widely considered as a safer alternative to conventional cigarettes, recent developments have brought to light potential harms associated with e-cigarette use.

“To the best of our knowledge, we currently do not know the recent smoking habits in American IBD patients, especially when it reveals that e-cigarette use might cause serious lung injuries,” they added.

In the present sample of 951 adult IBD patients, 5.0 percent (95 percent confidence interval [CI], 3.1–6.9) reported current use of e-cigarettes, yielding a population estimate of 152,020 users out of the 3,036,608-person total. [CCC 2020, abstract P032]

An intermittent e-cigarette habit was slightly more common, with 2.6 percent of the participants reporting use during some days. This corresponded to a population estimate of 80,252 people. On the other hand, 2.4 percent of the respondents reported everyday use, corresponding to an estimated 71,768 daily users in a 3 million-people population.

The use of combustible cigarettes, in comparison, remained more popular. The overall prevalence of conventional smoking was 17.9 percent with a population estimate of 557,387 people. A daily habit was much more common than some-day smoking (15.3 percent vs 2.6 percent).

Dual use of both conventional and electronic cigarettes was reported in 3.2 percent of the participants, yielding a population estimate of 96,681 people. This was more common than using only e-cigarettes (1.8 percent; population estimate, 55,339 people) but far less so than conventional smoking alone (14.9 percent; population estimate, 453,366 people).

Most participants used neither conventional nor electronic cigarettes (80.1 percent; population estimate: 2,430,152).

“While numerous studies show [that] e-cigarette use is generally increasing rapidly in the US, we found that 5 percent of IBD patients are currently using e-cigarette,” said the researchers, pointing out that concomitant use with combustible cigarettes was also relatively common.

“It is possible that most of the e-cigarette users are still in the process of transitioning from cigarette smoking and thus using both types,” they offered.

In the present study, the researchers retrieved participant data from the National Health Interview Study, a nationally representative survey of noninstitutionalized adults in America. Only those that had been diagnosed by their physicians as having IBD were eligible.

“We lack information on effects of using e-cigarette or both e-cigarette and cigarette in IBD treatment outcomes, as well as how e-cigarette use will complicate other health risks in IBD patients,” the researchers said. “We need further research on these effects to properly guide IBD patients who are in need of smoking cessation.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.